MétaCan
Menu
← Back to cohort
Record W4213139324 · doi:10.1093/jcag/gwab049.245

A246 GASTROINTESTINAL ADVERSE EVENTS OF CANNABINOIDS IN PEDIATRIC POPULATIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS

2022· review· en· W4213139324 on OpenAlexaff
Elyanne M. Ratcliffe, Parsa Karimi, M.K. Sunil, Russell Leong, José L. Ramírez-GarcíaLuna, Gregorio Zúñiga-Villanueva

Bibliographic record

VenueJournal of the Canadian Association of Gastroenterology · 2022
Typereview
Languageen
FieldMedicine
TopicCannabis and Cannabinoid Research
Canadian institutionsMcGill University Health CentreMcMaster University
Fundersnot available
KeywordsMedicineAdverse effectCochrane LibraryMeta-analysisConstipationPopulationNauseaVomitingCannabisInternal medicineMEDLINEAbdominal painPediatricsPsychiatry

Abstract

fetched live from OpenAlex

Abstract Background Use of therapeutic cannabinoids in the pediatric population has increased in recent years within areas of epilepsy, palliative care, and cancer. Given the endocannabinoid system plays a crucial role in gastrointestinal (GI) homeostasis, exogenous cannabinoids have the potential to develop GI related side effects. While some GI adverse events have been reported with the use of therapeutic cannabinoids, the full profile of GI adverse events in the pediatric population is still unknown. Aims To understand the impact of therapeutic cannabinoids on the GI system of pediatric patients, we performed a systematic review and meta-analysis to assess the prevalence of various GI-related adverse events arising from cannabinoid usage within pediatric populations. Methods Searches were conducted from OVID MEDLINE, EMBASE, CINAHL, Web of Science, and The Cochrane Library for study screening. The included studies were quantitatively assessed for GI adverse events including nausea, diarrhea, increased appetite, decreased appetite, weight gain, weight loss, constipation, abdominal pain, and unspecified events. The prevalence along with their relation towards diagnosis, type of cannabinoid, dosage, duration of treatment, and study type were also assessed. Results Among a total of 1201 patients across 25 included studies, an overall prevalence of 33.91% GI adverse events was observed in patients. The statistical analysis of the pediatric population displayed no relation between therapeutic cannabinoid usage and GI adverse events, bearing a large heterogeneity (I2 = 91%, P < 0.01). Upon analysis based on study type, a significant difference was observed between prospective and retrospective studies in categories of all GI adverse events, diarrhea, and decreased appetite, with prospective studies displaying a higher prevalence in all three categories. Nausea symptoms showed a significant negative correlation with maximum dosage of cannabinoid used. In addition, diarrhea was found to have a higher prevalence in Dravet syndrome related to an ion channel gene mutation (SCN1A) compared to other epilepsy patients. Conclusions While the meta-analysis did not identify any significant associations between therapeutic cannabinoid usage and GI adverse events, there remains the potential for interactions of cannabinoids on GI symptoms depending on dosage and underlying patient factors. Funding Agencies Farncombe Family Digestive Health Research Institute

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.009
metaresearch head score (Gemma)0.025
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.013
Threshold uncertainty score0.046

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0090.025
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0130.030
Bibliometrics0.0060.008
Science and technology studies0.0010.001
Scholarly communication0.0030.002
Open science0.0020.001
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0050.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.057
GPT teacher head0.335
Teacher spread0.279 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueJournal of the Canadian Association of Gastroenterology→Same topicCannabis and Cannabinoid Research→French-language works237,207→